1. Home
  2. BWXT vs GMAB Comparison

BWXT vs GMAB Comparison

Compare BWXT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BWX Technologies Inc.

BWXT

BWX Technologies Inc.

HOLD

Current Price

$217.47

Market Cap

17.8B

Sector

N/A

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$26.50

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWXT
GMAB
Founded
1867
1999
Country
United States
Denmark
Employees
N/A
3029
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8B
16.9B
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
BWXT
GMAB
Price
$217.47
$26.50
Analyst Decision
Buy
Strong Buy
Analyst Count
11
8
Target Price
$209.70
$39.56
AVG Volume (30 Days)
857.5K
1.5M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
0.52%
N/A
EPS Growth
16.61
N/A
EPS
3.58
N/A
Revenue
$1,687,738,000.00
N/A
Revenue This Year
$20.47
$17.85
Revenue Next Year
$9.50
$16.04
P/E Ratio
$60.22
$1.90
Revenue Growth
N/A
N/A
52 Week Low
$102.42
$18.89
52 Week High
$241.82
$35.43

Technical Indicators

Market Signals
Indicator
BWXT
GMAB
Relative Strength Index (RSI) 48.58 42.18
Support Level $187.96 $24.95
Resistance Level $219.10 $29.64
Average True Range (ATR) 8.61 0.55
MACD -2.32 -0.16
Stochastic Oscillator 30.22 20.89

Price Performance

Historical Comparison
BWXT
GMAB

About BWXT BWX Technologies Inc.

BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations. The Government Operations segment produces naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program, while the Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. The majority of the company's revenue comes from Government Operations, with sales principally in the United States, Canada, and other regions.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: